TransAlta Declares Dividends
The Board of Directors also declared the following quarterly dividend on its Cumulative Redeemable Rate Reset First Preferred Shares for the period starting from and including June 30, 2025, up to but excluding Sept. 30, 2025:
* Please note the quarterly floating rate on the Series B and Series D Preferred Shares will be reset every quarter.
All currency is expressed in Canadian dollars. When the dividend payment date falls on a weekend or holiday the payment is made the following business day.
About TransAlta Corporation:
TransAlta owns, operates and develops a diverse fleet of electrical power generation assets in Canada, the United States and Australia with a focus on long-term shareholder value. TransAlta provides municipalities, medium and large industries, businesses and utility customers with affordable, energy efficient and reliable power. Today, TransAlta is one of Canada's largest producers of wind power and Alberta's largest producer of thermal generation and hydro-electric power. For over 114 years, TransAlta has been a responsible operator and a proud member of the communities where we operate and where our employees work and live. TransAlta aligns its corporate goals with the UN Sustainable Development Goals and the Future-Fit Business Benchmark, which also defines sustainable goals for businesses. Our reporting on climate change management has been guided by the International Financial Reporting Standards (IFRS) S2 Climate-related Disclosures Standard and the Task Force on Climate-related Financial Disclosures (TCFD) recommendations. TransAlta has achieved a 70 per cent reduction in GHG emissions or 22.7 million tonnes CO2e since 2015 and received an upgraded MSCI ESG rating of AA.
For more information about TransAlta, visit our web site at
transalta.com
.
For more information:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
10 minutes ago
- UPI
Trump threatens trade deal over Canada's Palestine stance
Canadian Prime Minister Mark Carney meets with U.S. President Donald Trump in the Oval Office at the White House on Tuesday, May 6, 2025. On Wednesday night, Trump threatened trade negotiations between their two countries after Carney said Canada would recognize a Palestinian state. File Photo by Francis Chung/UPI | License Photo July 31 (UPI) -- President Donald Trump late Wednesday threatened the potential of a trade deal between the United States and Canada, after Ottawa said it would recognize a Palestinian state. Canadian Prime Minister Mark Carney made the announcement earlier Wednesday, stating it would officially make the mostly symbolic move in September at the United Nations General Assembly. Trump took to his Truth Social late Wednesday to deride the announcement. "Wow!" he said in the statement. "That will make it very hard for us to make a Trade Deal with them." Canada and the United States have been in an escalating trade war since Trump came into office in January, and repeatedly slapped tariffs on the United States closest ally and one of its most significant trading partners, with an additional 35% tariff set to go into effect Friday unless a deal is struck first. Carney, whose Liberal Party won the federal election in late April while riding an anti-Trump sentiment, has since sought to lessen Ottawa's dependency on Washington, while referring to Trump's stance toward his northern neighbor as a "betrayal." The two countries have been in trade negotiations since late June, after Carney shelved the Digital Services Tax, with expectations of having a deal finished by July 21. During the press conference Wednesday when he announced the decision to recognize a Palestinian state, Carney said they were still working to reach a deal with the United States. "Negotiations will continue until we do," he said, adding that his top trade officials will remain in Washington "in pursuit of that goal." Trump has staunchly objected to a Palestinian state and has been an ally to Prime Minister Benjamin Netanyahu and his war against Hamas in Gaza. The American president's warning came as his so-called Liberation Day tariffs were set to go into effect for countries that have yet to make a deal with the United States. Britain, the European Union and South Korea are among some of the countries that were successful in carving out deals with the American president ahead of Friday. Trump has already imposed a 25% tariff on all Canadian imports not subject to the Canada-United States-Mexico Agreement, as well as a 10% tariff on energy products, a 25% tariff on all cars and trucks built north of the border and a 50% tariff on aluminum and steel imports. Canada has responded with a slew of retaliatory tariffs, while specific provinces have banned alcohol from the United States. Several countries have come forward to recognize a Palestinian state as the war has dragged on and the death toll has continued to climb. Spain, Norway and Ireland formally recognized Palestinian statehood in late May, with France announcing it would recognize a Palestinian state late last week. And Britain has recently said it will recognize a Palestinian state if a cease-fire doesn't come into effect soon. The war began Oct. 7, 2023, when Hamas attacked Israel, killing 1,200 people and taking 251 others hostage. Since then, Israel has devastated Gaza, killing some 60,000 people.
Yahoo
15 minutes ago
- Yahoo
Why Eli Lilly Stock Was Looking Sickly Today
Key Points Investors were spooked by a peer's notable reduction in sales and profitability guidance. This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity. 10 stocks we like better than Eli Lilly › One of the more popular stocks in the pharmaceutical sector of late got the cold shoulder from investors on Tuesday. Eli Lilly (NYSE: LLY) closed today's trading session down by almost 6% in value, which was notably worse than the 0.3% drop of the bellwether S&P 500 index. That decline wasn't necessarily Eli Lilly's fault, though. Reducing weight, reducing guidance Eli Lilly's recent popularity is due in no small measure to its plunge into the highly lucrative weight-loss drug market. In late 2023, its Zepbound -- essentially the same treatment as its diabetes drug Mounjaro -- was approved to treat obesity, and the company was off to the races. On Tuesday, though, the standard-bearer for the segment took quite a tumble. That was Novo Nordisk, which this morning lowered its guidance for both full-year sales and operating profit. The growth forecast for the former was reduced to 8% to 14% over the 2024 tally (previous guidance range: 13% to 21%). Ditto for operating profit, which is now expected to rise in a range of 10% to 16%. That would be encouraging, if it weren't for the fact that management's preceding prediction was 16% to 24%. Novo Nordisk is known for developing and selling Wegovy, the first GLP-1 drug approved by the U.S. Food and Drug Administration specifically for weight loss. The company has flown to renown and admiration on the wings of that drug, which remains a key product. Investors probably fear that Eli Lilly's Zepbound will also perform worse than expected. Not an emergency I don't think anyone should push the panic button on Eli Lilly due to this (or Novo Nordisk, while I'm at it). Demand for obesity drugs remains strong and nearly unlimited, so both Zepbound and Wegovy -- which still benefit from a lack of competitors, at least for now -- should continue to be growth drivers. Also, in the case of Eli Lilly, the sprawling pharmaceutical company has a vast portfolio and a very wide development pipeline, so it's hardly dependent on one drug -- no matter how currently popular that drug might be. Should you buy stock in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $633,452!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,083,392!* Now, it's worth noting Stock Advisor's total average return is 1,046% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Eli Lilly Stock Was Looking Sickly Today was originally published by The Motley Fool
Yahoo
31 minutes ago
- Yahoo
Why Stanley Black & Decker Stock Tumbled by 7% on Tuesday
Key Points Tariffs are taking quite a toll on the company. Despite a bottom-line beat for its second quarter, profitability fell during the period. 10 stocks we like better than Stanley Black & Decker › Despite decades of experience and renown as a toolmaker, Stanley Black & Decker (NYSE: SWK) couldn't fix investors' sentiment about its stock Tuesday. On the back of dispiriting second-quarter results published this morning, those folks sold out of the company's shares, leaving a more than 7% slide in price. That was a far steeper fall than the S&P 500 index's 0.3% dip. It's tough living with tariffs Stanley Black & Decker's just-reported quarter saw the company book revenue of $3.9 billion, which was down by 2% year over year. Management attributed this to a sluggish outdoor buying season, combined with shipment disruptions directly related to the tariffs imposed by the current presidential administration. Similarly, profitability also obeyed gravity. Adjusted net income slipped by almost 1% to slightly over $163 million, or $1.08 per share. The consensus analyst estimate for revenue was $4 billion, while it was $0.41 for adjusted profitability. In the earnings release, management pledged to overcome the company's current difficulties. It quoted current chief operating officer and incoming CEO Christopher Nelson as saying that it "is executing a robust plan designed to mitigate tariffs and is prioritizing adjustments to its supply chain that leverage the strength of our North American footprint while optimizing our overseas supply chain inputs for the U.S. market." Annual profit prediction Stanley Black & Decker also proffered guidance for the entirety of 2025, predicting that it will earn roughly $4.65 per share in adjusted net income. That might see some adjustment, since it's predicated on an approximately $800 million financial hit from tariffs during the year. Considering the speed with which President Donald Trump has negotiated down certain rates, however, levies on our trading partners might have considerably less impact as 2025 wears on. Should you invest $1,000 in Stanley Black & Decker right now? Before you buy stock in Stanley Black & Decker, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Stanley Black & Decker wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $633,452!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,083,392!* Now, it's worth noting Stock Advisor's total average return is 1,046% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Stanley Black & Decker Stock Tumbled by 7% on Tuesday was originally published by The Motley Fool Sign in to access your portfolio
